NFKB2 Antibody

NFKB2

CVID10 antibody; DNA binding factor KBF2 antibody; DNA-binding factor KBF2 antibody; H2TF1 antibody; Lymphocyte translocation chromosome 10 antibody; Lymphocyte translocation chromosome 10 protein antibody; Lyt 10 antibody; Lyt10 antibody; NF kB2 antibody; NFKB2 antibody; NFKB2_HUMAN antibody; Nuclear factor NF kappa B p100 subunit antibody; Nuclear factor NF kappa B p52 subunit antibody; Nuclear factor NF-kappa-B p52 subunit antibody; Nuclear factor of kappa light chain gene enhancer in B cells 2 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 antibody; Oncogene Lyt 10 antibody; Oncogene Lyt-10 antibody; p105 antibody; p49/p100 antibody

Recombinant Human Nuclear factor NF-kappa-B p100 subunit protein (263-439AA)

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form, the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.

>95%, Protein G purified

Cell Biology

Recombinant Human Nuclear factor NF-kappa-B p100 subunit protein (263-439AA)